Insulet (NASDAQ:PODD) Coverage Initiated by Analysts at Deutsche Bank Aktiengesellschaft

Investment analysts at Deutsche Bank Aktiengesellschaft initiated coverage on shares of Insulet (NASDAQ:PODD) in a research note issued on Tuesday. The firm set a “buy” rating and a $190.00 price target on the medical instruments supplier’s stock. Deutsche Bank Aktiengesellschaft’s target price indicates a potential upside of 36.72% from the stock’s previous close.

A number of other equities research analysts have also issued reports on the stock. Sanford C. Bernstein dropped their target price on shares of Insulet from $330.00 to $200.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Citigroup decreased their price target on shares of Insulet from $175.00 to $165.00 and set a “neutral” rating on the stock in a research note on Thursday, May 28th. Stifel Nicolaus lowered their price target on shares of Insulet from $350.00 to $250.00 in a research report on Thursday, May 7th. Barclays dropped their price objective on shares of Insulet from $286.00 to $198.00 and set an “underweight” rating for the company in a research note on Thursday, May 7th. Finally, Evercore cut their price objective on shares of Insulet from $240.00 to $200.00 in a report on Thursday, May 7th. Twenty-two equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Insulet has a consensus rating of “Moderate Buy” and an average price target of $238.67.

Insulet Stock Performance

NASDAQ PODD opened at $138.97 on Tuesday. The company has a market cap of $9.63 billion, a PE ratio of 32.32, a price-to-earnings-growth ratio of 1.15 and a beta of 1.13. The stock’s 50 day simple moving average is $162.97 and its 200-day simple moving average is $224.47. Insulet has a 1-year low of $138.79 and a 1-year high of $354.88. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The firm had revenue of $761.70 million for the quarter, compared to analyst estimates of $729.89 million. During the same period in the previous year, the company posted $1.02 earnings per share. The business’s revenue was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, equities research analysts anticipate that Insulet will post 6.46 EPS for the current fiscal year.

Insider Activity at Insulet

In related news, Director Timothy C. Stonesifer purchased 2,790 shares of Insulet stock in a transaction dated Wednesday, June 3rd. The shares were acquired at an average price of $143.51 per share, for a total transaction of $400,392.90. Following the acquisition, the director directly owned 9,041 shares in the company, valued at approximately $1,297,473.91. The trade was a 44.63% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.36% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Insulet

A number of hedge funds have recently modified their holdings of the company. Larson Financial Group LLC boosted its holdings in Insulet by 114.6% in the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 47 shares during the last quarter. University of Texas Texas AM Investment Management Co. acquired a new stake in shares of Insulet during the 4th quarter worth approximately $26,000. DV Equities LLC purchased a new stake in shares of Insulet during the 4th quarter valued at approximately $28,000. Elyxium Wealth LLC purchased a new stake in shares of Insulet during the 4th quarter valued at approximately $28,000. Finally, Mcguire Capital Advisors Inc. acquired a new position in Insulet in the fourth quarter valued at approximately $29,000.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.